Search clinical trials for: Inhibitor receptora śródbłonkowego czynnika wzrostu pan-naczyniowego (VEGFR)

Total 79610 results

AstraZeneca

Active, not recruiting

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific (AURA17)

Non-Small Cell Lung Cancer

Korea, Republic of, China, Australia
National Taiwan University Hospital

Completed

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Tumor Progression | EGFR Exon 19 Mutation

Taiwan
Celcuity, Inc.

Completed

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Breast Cancer

United States
Hoffmann-La Roche

Terminated

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy (Veronica)

Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

Canada, United States, United Kingdom, Australia, Germany
Incyte Corporation

Terminated

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma

Spain, France, United States, Italy, Japan, Ireland, Slovakia, Austria, Belgium, Canada, Finland, Germany, Poland, Portugal, Romania, United Kingdom
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

United States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
Novartis Pharmaceuticals

Completed

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Neoplasms, Breast

United States
Novartis Pharmaceuticals

Completed

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Advanced Metastatic Breast Cancer

Germany
Novartis Pharmaceuticals
Breast International Group; SOLTI Breast Cancer Research Group

Completed

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (Neo ALTTO)

Neoplasms, Breast

France, Spain, United Kingdom, Belgium, Argentina, Czechia, Germany, Italy, Norway, Russian Federation, Sweden, Taiwan, Hong Kong, Brazil, Hungary, India, Korea, Republic of, Pakistan, Peru, Romania, South Africa, Ukraine, Canada, Lit...
Korea University Guro Hospital
Chong Kun Dang Pharmaceutical Corp.

Active, not recruiting

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Centre Leon Berard

Completed

Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR) (CICAFIX)

Colorectal Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Epidermal Growth Factor Receptor Inhibitor

France
Exelixis

Completed

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)

Renal Cell Carcinoma

United States, Belgium, Spain, Taiwan, Canada, Germany, Korea, Republic of, France, Austria, Chile, Australia, Hungary, Russian Federation, Italy, Turkey, Netherlands, Sweden, United Kingdom, Czechia, Ireland, Slovakia, Argentina, D... and more
Novartis Pharmaceuticals

Completed

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (BOLERO-6)

Breast Cancer

Belgium, Hungary, Spain, Argentina, Russian Federation, Sweden, Lebanon, Australia, Denmark, Ireland, United Kingdom, Thailand, Turkey, Peru, Brazil, Malaysia, India, United States
Novartis Pharmaceuticals

Completed

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Breast Neoplasms

United States, France, Spain, United Kingdom, Croatia, Turkey, Netherlands, Argentina, Australia, Canada, Czechia, Germany, Italy, Poland, Russian Federation, Brazil, Bulgaria, Chile, Denmark, Hungary, Ireland, Peru, South Africa, Col... and more
First Affiliated Hospital of Harbin Medical University

Unknown

Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia

Coronary Artery Disease

China
National Taiwan University Hospital

Completed

The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer

Tumor Progression

Taiwan
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor Mutations

United States
Astellas Pharma Inc

Terminated

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer

Japan, Korea, Republic of, Taiwan
Novartis Pharmaceuticals

Terminated

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Cancer

United States, Canada
Haihua Yang

Unknown

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
SOLTI Breast Cancer Research Group
Novartis

Completed

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

Breast Cancer

Spain
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) Mutations

United States
Vyne Therapeutics Inc.

Completed

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Rash Due to Epidermal Growth Factor Receptor Inhibitors

Israel
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Solid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
Chinese Society of Lung Cancer
Guangdong Provincial People's Hospital

Completed

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Thoracic Neoplasms

China
GlaxoSmithKline

Completed

A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects

Irritable Bowel Syndrome

Australia
Hangzhou Cancer Hospital

Unknown

RT Plus EGFR-TKI for Wild-type NSCLC

Non-small Cell Lung Cancer | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

China
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Metastatic Pancreatic Carcinoma

United States
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Terminated

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Breast Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Recurrent Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Lung Squamous Cell Carcinoma
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Metastatic Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8

United States
Rigshospitalet, Denmark
Aarhus University Hospital Skejby

Recruiting

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4) (NOTION-4)

Heart Diseases | Cardiovascular Diseases | Aortic Valve Stenosis | Heart Valve Diseases | Valve Disease, Aortic

Denmark
M.D. Anderson Cancer Center

Not yet recruiting

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Hormone Receptor-positive Human Epidermal Growth Factor 2-negative | Metastatic Invasive LObular Carcinoma

United States
Bayer

Recruiting

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

Australia, China, Korea, Republic of, Taiwan
University of Chicago

Not yet recruiting

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast Cancer | HER2-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
BioNTech SE
DualityBio Inc.

Not yet recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Endometrial Cancer
Taizhou Hospital

Not yet recruiting

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Lung Cancer, Nonsmall Cell
Mridula George, MD

Recruiting

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Breast Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand
Zunyi Medical College

Recruiting

Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus

STEMI - ST Elevation Myocardial Infarction

China
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Xijing Hospital

Recruiting

Low-dose NOAC Versus GDMT After LAAO (RECORD-III)

Atrial Fibrillation

China
University of Calgary
Alimentiv Inc.

Recruiting

PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Crohn Disease

Canada
Artios Pharma Ltd

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors. (SkinHealth)

Melanoma | Kidney Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Bladder Cancer | Skin Cancer | Head Neck Cancer

Italy
Taipei Veterans General Hospital, Taiwan

Not yet recruiting

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Carcinoma, Non-Small-Cell Lung | Leptomeningeal Metastasis | Epidermal Growth Factor Receptor

Search clinical trials for: Inhibitor receptora śródbłonkowego czynnika wzrostu pan-naczyniowego (VEGFR)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations